GenoMar Genetics AS, a wholly-owned subsidiary of EW Group GmbH, acquired the genetics and distribution assets of AquaAmérica and AquaPorto, an independent Brazilian company for genetic improvement and distribution of tilapia, based in Minas Gerais.
As part of the agreement, AquaAmérica's breeding program and genetics will join a portfolio of major tilapia brands, including GenoMar Supreme and Aquabel, which will be managed by Genomar's research and development team. AquaAmérica will become an independent distribution company with separate commercial activities.
“I am very proud to be part of an organization with a worldwide presence, such as GenoMar and EW Group. We are looking forward to using experience and knowledge in technology, production and distribution to offer generations of tilapia with constant genetic improvements to our customers,” said Jorge Barbosa, AquaAmérica CEO. “We share with GenoMar the definitive vision of making the tilapia sector a sustainable and economical supplier to the domestic and global markets, where Brazil has been standing out in recent years as a star on the global tilapia scene. As a result, our responsibility to provide safety and quality to our customers becomes more important than ever. GenoMar has the resources, experience and long-term vision to accomplish this.”
“AquaAmérica's breeding program, leadership team and distribution infrastructure will contribute enormously to our expanding businesses in the region. We hope to share knowledge, technology and resources to further improve AquaAmérica's position in Brazil and Latin America. A new genetic improvement center is under construction and will be AquaAmérica's new genetic home. This will ensure the implementation of modern breeding technologies and the allocation of resources in the long term. We will also be investing in the existing distribution infrastructure to benefit customers of AquaAmérica genetics. The two companies will continue to work to support their customers, without interruptions in supply and services,” said Alejandro Tola Alvarez, CEO of GenoMar Genetics Group.
